Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 1
2015 1
2016 1
2017 4
2018 2
2019 7
2020 17
2021 23
2022 11
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean chen liang zhou (18 results)?
Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma.
Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z, Wang Y, Zhang Z, Yuan T, Ding X, Tang L, Zhang J, Yin J, Huang Y, Yu W, Wang Y, Zhou C, Su Y, He A, Sun Y, Shen Z, Qian B, Meng W, Fei J, Yao Y, Pan X, Chen P, Hu H. Zhou Y, et al. Among authors: zhou c. Nat Commun. 2020 Dec 10;11(1):6322. doi: 10.1038/s41467-020-20059-6. Nat Commun. 2020. PMID: 33303760 Free PMC article.
Author Correction: Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma.
Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z, Wang Y, Zhang Z, Yuan T, Ding X, Tang L, Zhang J, Yin J, Huang Y, Yu W, Wang Y, Zhou C, Su Y, He A, Sun Y, Shen Z, Qian B, Meng W, Fei J, Yao Y, Pan X, Chen P, Hu H. Zhou Y, et al. Among authors: zhou c. Nat Commun. 2021 Apr 30;12(1):2567. doi: 10.1038/s41467-021-23119-7. Nat Commun. 2021. PMID: 33931654 Free PMC article. No abstract available.
First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001.
Zhou Y, Yang Q, Dong Y, Ji T, Zhang B, Yang C, Zheng S, Tang L, Zhou C, Qian G, Huang Y, Yu W, Li H, Wang Y, He A, Shen Z, Bao Q, Hua Y, Bai H, Zhao J, Li X, Dai X, Zhang J, Hu H, Yao Y. Zhou Y, et al. Among authors: zhou c. Clin Cancer Res. 2023 Feb 16;29(4):764-774. doi: 10.1158/1078-0432.CCR-22-2470. Clin Cancer Res. 2023. PMID: 36469563 Clinical Trial.
A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas.
Zhou Y, Li M, Zhang B, Yang C, Wang Y, Zheng S, Tang L, Zhou C, Qian G, Huang Y, Yu W, Li H, Wang Y, He A, Shen Z, Zhang J, Li X, Yang Q, Hu H, Yao Y. Zhou Y, et al. Among authors: zhou c. BMC Med. 2023 Nov 29;21(1):470. doi: 10.1186/s12916-023-03132-x. BMC Med. 2023. PMID: 38031088 Free PMC article. Clinical Trial.
A potent, broadly protective vaccine against SARS-CoV-2 variants of concern.
Wang Z, An J, Liu K, Yu P, Fang X, Li J, Zhu H, Zhu Q, Huang C, Zhang C, Zhao B, Bao L, Song Y, Cao X, Hu D, Jiang Y, Shi L, Zhou L, Fan J, Guan W, Zhou C, Hu Z, Yuan Z, Liu J, Shan C, Liu G. Wang Z, et al. Among authors: zhou c. NPJ Vaccines. 2022 Nov 12;7(1):144. doi: 10.1038/s41541-022-00571-0. NPJ Vaccines. 2022. PMID: 36371432 Free PMC article.
74 results